The COVID-19 pandemic has led to a need for alternative routes of drug administration for end of life and palliative care. This has brought stakeholders in the oral transmucosal drugs market under scrutiny, especially in community settings. Popular transmucosal routes such as buccal, intranasal, sublingual, and rectal are being publicized. This has led to the scope of non-invasive routes for systematic drug delivery with the potential for self-administration or administration by family caregivers.
Companies in the oral transmucosal drugs market are capitalizing on the ability to offer rapid onset of action with reduced first-pass metabolism. Oral transmucosal drugs are being increasingly used in palliative and end of life care to provide fast relief of symptoms. Such findings are benefitting healthcare providers during the coronavirus outbreak, since the health of some patients tends to deteriorate rapidly in certain cases.
The successful delivery of drugs across the oral mucosa represents a continuing challenge as well as an opportunity for stakeholders in the oral transmucosal drugs market. This explains why the market is estimated to clock a favorable CAGR of ~6% during the forecast period. Hence, companies are expected to collaborate with researchers, scientists, and biologists to increase R&D in novel mucoadhesive polymers. They are increasing efforts to design improved drug delivery systems that achieve delivery through the different mucosa.
Transmucosal drug delivery systems are gaining increased popularity, as mucous membranes are relatively permeable, which facilitate the rapid uptake of a drug into the systemic circulation. Companies are boosting their production capabilities in mucoadhesive polymers under different dosage forms such as tablets, films, semisolids, and powders.
Despite the number of advantages linked with transmucosal drug delivery, the medicines delivered as buccal or sublingual formulations remain relatively low. Aquestive Therapeutics - a specialty pharmaceutical company is finding opportunity in this challenge, and increasing its focus on developing novel permeation enhancers, stabilizers, and polymer blends that can boost the ability of active ingredients to penetrate the mucosa. Such innovations explain why the oral transmucosal drugs market is expected to reach US$ 27 Bn by 2031.
Proprietary compositional profiles of oral films are being tailored to the buccal or sublingual microenvironment in order to achieve a desired rate of absorption. This is evident since buccal films are likely to dominate the second-highest revenue among all drug types in the oral transmucosal drugs market.
Extensive research is being carried out on the design and development of innovative drug delivery systems to improve their efficacy, safety, and patient compliance. Buccal films are the most recently developed dosage form for buccal administration. Companies in the oral transmucosal drugs market are capitalizing on this opportunity, since buccal films are gaining importance as efficacious and novel drug delivery systems that are cost-efficient and enable good patient compliance.
As buccal films are implied for attachment to the buccal mucosa, they can be formulated to exhibit local as well as systemic action. Pharmaceutical companies in the oral transmucosal drugs market are bolstering their output capacities in buccal films, since they are being preferred over buccal tablets, owing to the former’s flexibility and comfort. It has been found that buccal films have direct access to the systemic circulation through the jugular vein, which bypasses the drug from the hepatic first pass metabolism leading to the high bioavailability.
Oral thin films are storming the oral transmucosal drugs market. CURE Pharmaceutical Holding Corp. is gaining popularity for its flagship technology CUREfilm® that is a thin oral film platform, which optimizes the absorption and metabolism of therapeutic actives. Companies are taking cues from such innovations, and focusing on the oral soluble film technology that offers a versatile dose form and allows manufacturers to create proprietary products with optimal release profiles. This ensures better patient outcomes with oral thin films and enhanced consumer experiences.
Companies in the oral transmucosal drugs market are increasing their production of oral thin films, attributed to ease of use, high load, precision dosing, and fast acting capacities.
The advanced materials for drug delivery across mucosal barriers are being developed by companies in the oral transmucosal drugs market. Mucus is a viscoelastic gel that traps pathogens and other foreign particles to limit their penetration into the underlying epithelium. On the other hand, dosage forms containing particle-based drug delivery systems are trapped in mucosal layers and tend to be removed by mucus turnover. This has driven companies in the oral transmucosal drugs market to increase their R&D activities in mucoadhesion, which helps to avoid premature wash-off and prolongs the residence time of drugs on mucus.
Mucoadhesion helps in mucus penetration, which is essential for molecules to access the underlying epithelial tissues. As such, various strategies are being investigated to achieve mucoadhesion and mucus penetration of drug carriers.
The pharmaceutical companies in the oral transmucosal drugs market are acquiring a strong research base in micro and nanoscale technologies. The smart and controlled oral drug deliveries are predicted to bypass the physiological barriers that limit the oral delivery of hydrophilic therapeutics. Micro and nanoscale technologies are known for their unprecedented ability to create, control, and measure micro- or nano-environments that have found increased number of applications in biology and medicine.
Micro and nanoscale drug carriers such as bioadhesives, microparticles and nano-particles are being developed by pharmaceutical companies. The integration of bioadhesive properties improves the oral drug delivery of fabricated carriers. One of the key purpose of utilizing bio-adhesive materials is to delay the transit of cargos to enable the sustainable release of drugs at target sites. This helps to prolong the residence time in order to enhance the drug absorption process.
Analysts’ Viewpoint
Though oral transmucosal drugs have the potential for self-administration in COVID-19 patients, it is met with challenges such as relatively small surface area for effective drug absorption. Companies are increasing their R&D activities to better the drug administration in coronavirus patients, since even after vaccination there is a high risk of reinfection in patients.
The oral administration is one of the most important pillars of the pharmaceutical industry. However, it is still challenging to administer hydrophilic therapeutics by the oral route. Hence, companies in the oral transmucosal drugs market should mainly focus on the design of carriers with bio-adhesive properties for oral transmucosal drugs and the administration of hydrophilic therapeutics.
Oral transmucosal drugs market is expected to reach US$ 27 billion by 2031
Oral transmucosal drugs market is anticipated to expand at a CAGR of 6% to 2021-2031
Oral transmucosal drugs market is driven by rise in prevalence of neurological disorders and chronic diseases, increase in geriatric population, and adoption of novel drug delivery systems
The buccal mucosa segment held major share of the global oral transmucosal drugs market
Top key players in oral transmucosal drugs market are LTS Lohmann Therapie-Systeme AG, Soligenix, ZIM Laboratories Limited, Access Pharmaceutical Inc., C.L Pharm, Seoul Pharmaceuticals, Cure Pharmaceutical, Aquestive Therapeutics, Inc.
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Oral Transmucosal Drugs Market
4. Market Overview
4.1. Introduction
4.1.1. Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Oral Transmucosal Drugs Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Key Mergers & Acquisitions
5.2. COVID-19 Pandemic Impact on Industry (value chain and short / mid / long term impact)
5.3. Top 3 players operating in the market space
5.4. Clinical Trials & Pipeline Analysis
5.5. Oral Transmucosal Drugs Market SWOT Analysis
6. Global Oral Transmucosal Drugs Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Type, 2017–2031
6.3.1. Tablets
6.3.1.1. Sublingual Tablets
6.3.1.2. Buccal Tablets
6.3.1.3. Lozenges & Troches
6.3.1.4. Others
6.3.2. Buccal Films
6.3.3. Liquid & Spray
6.3.3.1. Aqueous Solutions
6.3.3.2. Suspensions
6.3.4. Gels
6.3.5. Others
6.4. Market Attractiveness Analysis, by Type
7. Global Oral Transmucosal Drugs Market Analysis and Forecast, by Route of Penetration
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Route of Penetration, 2017–2031
7.3.1. Sublingual Mucosa
7.3.2. Buccal Mucosa
7.3.3. Gingival Tissues
7.3.4. Palatal Tissues
7.4. Market Attractiveness Analysis, by Route of Penetration
8. Global Oral Transmucosal Drugs Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Oral Transmucosal Drugs Market Analysis and Forecast, by Indication
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Indication, 2017–2031
9.3.1. Cardiovascular Disorders
9.3.2. Acute Pain Management
9.3.3. Sedation
9.3.4. Erectile Dysfunction
9.3.5. Diabetes
9.3.6. Others
9.4. Market Attractiveness Analysis, by Indication
10. Global Oral Transmucosal Drugs Market Analysis and Forecast, by Region
10.1. Key Findings
10.2. Market Value Forecast, by Region
10.2.1. North America
10.2.2. Europe
10.2.3. Asia Pacific
10.2.4. South Korea
10.2.5. Latin America
10.2.6. Middle East & Africa
10.3. Market Attractiveness Analysis, by Country/Region
11. North America Oral Transmucosal Drugs Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Type, 2017–2031
11.2.1. Tablets
11.2.1.1. Sublingual Tablets
11.2.1.2. Buccal Tablets
11.2.1.3. Lozenges & Troches
11.2.1.4. Others
11.2.2. Buccal Films
11.2.3. Liquid & Spray
11.2.3.1. Aqueous Solutions
11.2.3.2. Suspensions
11.2.4. Gels
11.2.5. Others
11.3. Market Value Forecast, by Route of Penetration, 2017–2031
11.3.1. Sublingual Mucosa
11.3.2. Buccal Mucosa
11.3.3. Gingival Tissues
11.3.4. Palatal Tissues
11.4. Market Value Forecast, by Distribution Channel, 2017–2031
11.4.1. Hospital Pharmacies
11.4.2. Retail Pharmacies
11.4.3. Online Pharmacies
11.5. Market Value Forecast, by Indication, 2017–2031
11.5.1. Cardiovascular Disorders
11.5.2. Acute Pain Management
11.5.3. Sedation
11.5.4. Erectile Dysfunction
11.5.5. Diabetes
11.5.6. Others
11.6. Market Value Forecast, by Country, 2017–2031
11.6.1. U.S.
11.6.2. Canada
11.7. Market Attractiveness Analysis
11.7.1. By Type
11.7.2. By Route of Penetration
11.7.3. By Distribution Channel
11.7.4. By Indication
11.7.5. By Country
12. Europe Oral Transmucosal Drugs Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Type, 2017–2031
12.2.1. Tablets
12.2.1.1. Sublingual Tablets
12.2.1.2. Buccal Tablets
12.2.1.3. Lozenges & Troches
12.2.1.4. Others
12.2.2. Buccal Films
12.2.3. Liquid & Spray
12.2.3.1. Aqueous Solutions
12.2.3.2. Suspensions
12.2.4. Gels
12.2.5. Others
12.3. Market Value Forecast, by Route of Penetration, 2017–2031
12.3.1. Sublingual Mucosa
12.3.2. Buccal Mucosa
12.3.3. Gingival Tissues
12.3.4. Palatal Tissues
12.4. Market Value Forecast, by Distribution Channel, 2017–2031
12.4.1. Hospital Pharmacies
12.4.2. Retail Pharmacies
12.4.3. Online Pharmacies
12.5. Market Value Forecast, by Indication, 2017–2031
12.5.1. Cardiovascular Disorders
12.5.2. Acute Pain Management
12.5.3. Sedation
12.5.4. Erectile Dysfunction
12.5.5. Diabetes
12.5.6. Others
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. Germany
12.6.2. U.K.
12.6.3. France
12.6.4. Italy
12.6.5. Spain
12.6.6. Rest of Europe
12.7. Market Attractiveness Analysis
12.7.1. By Type
12.7.2. By Route of Penetration
12.7.3. By Distribution Channel
12.7.4. By Indication
12.7.5. By Country/Sub-region
13. Asia Pacific Oral Transmucosal Drugs Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Type, 2017–2031
13.2.1. Tablets
13.2.1.1. Sublingual Tablets
13.2.1.2. Buccal Tablets
13.2.1.3. Lozenges & Troches
13.2.1.4. Others
13.2.2. Buccal Films
13.2.3. Liquid & Spray
13.2.3.1. Aqueous Solutions
13.2.3.2. Suspensions
13.2.4. Gels
13.2.5. Others
13.3. Market Value Forecast, by Route of Penetration, 2017–2031
13.3.1. Sublingual Mucosa
13.3.2. Buccal Mucosa
13.3.3. Gingival Tissues
13.3.4. Palatal Tissues
13.4. Market Value Forecast, by Distribution Channel, 2017–2031
13.4.1. Hospital Pharmacies
13.4.2. Retail Pharmacies
13.4.3. Online Pharmacies
13.5. Market Value Forecast, by Indication, 2017–2031
13.5.1. Cardiovascular Disorders
13.5.2. Acute Pain Management
13.5.3. Sedation
13.5.4. Erectile Dysfunction
13.5.5. Diabetes
13.5.6. Others
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. Japan
13.6.2. China
13.6.3. India
13.6.4. Australia & New Zealand
13.6.5. South Korea
13.6.6. Rest of Asia Pacific
13.7. Market Attractiveness Analysis
13.7.1. By Type
13.7.2. By Route of Penetration
13.7.3. By Distribution Channel
13.7.4. By Indication
13.7.5. By Country/Sub-region
14. Latin America Oral Transmucosal Drugs Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Type, 2017–2031
14.2.1. Tablets
14.2.1.1. Sublingual Tablets
14.2.1.2. Buccal Tablets
14.2.1.3. Lozenges & Troches
14.2.1.4. Others
14.2.2. Buccal Films
14.2.3. Liquid & Spray
14.2.3.1. Aqueous Solutions
14.2.3.2. Suspensions
14.2.4. Gels
14.2.5. Others
14.3. Market Value Forecast, by Route of Penetration, 2017–2031
14.3.1. Sublingual Mucosa
14.3.2. Buccal Mucosa
14.3.3. Gingival Tissues
14.3.4. Palatal Tissues
14.4. Market Value Forecast, by Distribution Channel, 2017–2031
14.4.1. Hospital Pharmacies
14.4.2. Retail Pharmacies
14.4.3. Online Pharmacies
14.5. Market Value Forecast, by Indication, 2017–2031
14.5.1. Cardiovascular Disorders
14.5.2. Acute Pain Management
14.5.3. Sedation
14.5.4. Erectile Dysfunction
14.5.5. Diabetes
14.5.6. Others
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. Brazil
14.6.2. Mexico
14.6.3. Rest of Latin America
14.7. Market Attractiveness Analysis
14.7.1. By Type
14.7.2. By Route of Penetration
14.7.3. By Distribution Channel
14.7.4. By Indication
14.7.5. By Country/Sub-region
15. Middle East & Africa Oral Transmucosal Drugs Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast, by Type, 2017–2031
15.2.1. Tablets
15.2.1.1. Sublingual Tablets
15.2.1.2. Buccal Tablets
15.2.1.3. Lozenges & Troches
15.2.1.4. Others
15.2.2. Buccal Films
15.2.3. Liquid & Spray
15.2.3.1. Aqueous Solutions
15.2.3.2. Suspensions
15.2.4. Gels
15.2.5. Others
15.3. Market Value Forecast, by Route of Penetration, 2017–2031
15.3.1. Sublingual Mucosa
15.3.2. Buccal Mucosa
15.3.3. Gingival Tissues
15.3.4. Palatal Tissues
15.4. Market Value Forecast, by Distribution Channel, 2017–2031
15.4.1. Hospital Pharmacies
15.4.2. Retail Pharmacies
15.4.3. Online Pharmacies
15.5. Market Value Forecast, by Indication, 2017–2031
15.5.1. Cardiovascular Disorders
15.5.2. Acute Pain Management
15.5.3. Sedation
15.5.4. Erectile Dysfunction
15.5.5. Diabetes
15.5.6. Others
15.6. Market Value Forecast, by Country/Sub-region, 2017–2031
15.6.1. GCC Countries
15.6.2. South Africa
15.6.3. Rest of Middle East & Africa
15.7. Market Attractiveness Analysis
15.7.1. By Type
15.7.2. By Route of Penetration
15.7.3. By Distribution Channel
15.7.4. By Indication
15.7.5. By Country/Sub-region
16. Competition Landscape
16.1. Market Share Analysis, by Company, 2020
16.2. Company Profiles
16.2.1. LTS Lohmann Therapie-Systeme AG
16.2.1.1. Company Overview
16.2.1.2. Company Financials
16.2.1.3. Growth Strategies
16.2.1.4. SWOT Analysis
16.2.2. Soligenix
16.2.2.1. Company Overview
16.2.2.2. Company Financials16.
16.2.2.3. Growth Strategies
16.2.2.4. SWOT Analysis
16.2.3. ZIM Laboratories Limited
16.2.3.1. Company Overview
16.2.3.2. Company Financials
16.2.3.3. Growth Strategies
16.2.3.4. SWOT Analysis
16.2.4. Access Pharmaceutical, Inc.
16.2.4.1. Company Overview
16.2.4.2. Company Financials
16.2.4.3. Growth Strategies
16.2.4.4. SWOT Analysis
16.2.5. C.L Pharm
16.2.5.1. Company Overview
16.2.5.2. Company Financials
16.2.5.3. Growth Strategies
16.2.5.4. SWOT Analysis
16.2.6. Seoul Pharmaceuticals
16.2.6.1. Company Overview
16.2.6.2. Company Financials
16.2.6.3. Growth Strategies
16.2.6.4. SWOT Analysis
16.2.7. Cure Pharmaceutical
16.2.7.1. Company Overview
16.2.7.2. Company Financials
16.2.7.3. Growth Strategies
16.2.7.4. SWOT Analysis
16.2.8. Aquestive Therapeutics, Inc.
16.2.8.1. Company Overview
16.2.8.2. Company Financials
16.2.8.3. Growth Strategies
16.2.8.4. SWOT Analysis
16.2.9. Solvay S.A.
16.2.9.1. Company Overview
16.2.9.2. Company Financials
16.2.9.3. Growth Strategies
16.2.9.4. SWOT Analysis
16.2.10. NAL Pharma
16.2.10.1. Company Overview
16.2.10.2. Company Financials
16.2.10.3. Growth Strategies
16.2.10.4. SWOT Analysis
16.2.11. IntelGenx Corp.
16.2.11.1. Company Overview
16.2.11.2. Company Financials
16.2.11.3. Growth Strategies
16.2.11.4. SWOT Analysis
16.2.12. Izun Pharmaceuticals
16.2.12.1. Company Overview
16.2.12.2. Company Financials
16.2.12.3. Growth Strategies
16.2.12.4. SWOT Analysis
16.2.13. Eisai Co., Ltd
16.2.13.1. Company Overview
16.2.13.2. Company Financials
16.2.13.3. Growth Strategies
16.2.13.4. SWOT Analysis
16.2.14. AstraZeneca
16.2.14.1. Company Overview
16.2.14.2. Company Financials
16.2.14.3. Growth Strategies
16.2.14.4. SWOT Analysis
16.2.15. Otsuka Pharmaceutical Co., Ltd.
16.2.15.1. Company Overview
16.2.15.2. Company Financials
16.2.15.3. Growth Strategies
16.2.15.4. SWOT Analysis
16.2.16. Pfizer, Inc.
16.2.16.1. Company Overview
16.2.16.2. Company Financials
16.2.16.3. Growth Strategies
16.2.16.4. SWOT Analysis
16.2.17. Teva Pharmaceutical Industries Ltd.
16.2.17.1. Company Overview
16.2.17.2. Company Financials
16.2.17.3. Growth Strategies
16.2.17.4. SWOT Analysis
16.2.18. GlaxoSmithKline plc
16.2.18.1. Company Overview
16.2.18.2. Company Financials
16.2.18.3. Growth Strategies
16.2.18.4. SWOT Analysis
16.2.19. Mylan N.V.
16.2.19.1. Company Overview
16.2.19.2. Company Financials
16.2.19.3. Growth Strategies
16.2.19.4. SWOT Analysis
16.2.20. Bristol-Myers Squibb Company
16.2.20.1. Company Overview
16.2.20.2. Company Financials
16.2.20.3. Growth Strategies
16.2.20.4. SWOT Analysis
List of Tables
Table 01: Global Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 02: Global Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Tablets, 2017–2031
Table 03: Global Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Liquid & Spray, 2017–2031
Table 04: Global Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Route of Penetration, 2017–2031
Table 05: Global Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 06: Global Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Indication, 2017–2031
Table 07: Global Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 08: North America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 09: North America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 10: North America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Tablets, 2017–2031
Table 11: North America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Liquid & Spray, 2017–2031
Table 12: North America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Route of Penetration, 2017–2031
Table 13: North America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 14: North America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Indication, 2017–2031
Table 15: Europe Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 16: Europe Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 17: Europe Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Tablets, 2017–2031
Table 18: Europe Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Liquid & Spray, 2017–2031
Table 19: Europe Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Route of Penetration, 2017–2031
Table 20: Europe Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 21: Europe Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Indication, 2017–2031
Table 22: Asia Pacific Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 23: Asia Pacific Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 24: Asia Pacific Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Tablets, 2017–2031
Table 25: Asia Pacific Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Liquid & Spray, 2017–2031
Table 26: Asia Pacific Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Route of Penetration, 2017–2031
Table 27: Asia Pacific Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 28: Asia Pacific Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Indication, 2017–2031
Table 29: Latin America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 30: Latin America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 31: Latin America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Tablets, 2017–2031
Table 32: Latin America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Liquid & Spray, 2017–2031
Table 33: Latin America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Route of Penetration, 2017–2031
Table 34: Latin America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 35: Latin America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Indication, 2017–2031
Table 36: Middle East & Africa Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 37: Middle East & Africa Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 38: Middle East & Africa Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Tablets, 2017–2031
Table 39: Middle East & Africa Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Liquid & Spray, 2017–2031
Table 40: Middle East & Africa Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Route of Penetration, 2017–2031
Table 41: Middle East & Africa Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Distribution Channel, 2017–2031
Table 42: Middle East & Africa Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, by Indication, 2017–2031
List of Figures
Figure 01: Global Oral Transmucosal Drugs Market Value (US$ Mn) Forecast, 2017–2031
Figure 02: Global Oral Transmucosal Drugs Market Value Share Analysis, by Type, 2020 and 2031
Figure 03: Global Oral Transmucosal Drugs Market Attractiveness Analysis, by Type, 2021–2031
Figure 04: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Tablets, 2017?2031
Figure 05: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Buccal Films, 2017?2031
Figure 06: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Liquid & Spray, 2017?2031
Figure 07: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Gels, 2017?2031
Figure 08: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Others, 2017?2031
Figure 09: Global Oral Transmucosal Drugs Market Value Share Analysis, by Route of Penetration, 2020 and 2031
Figure 10: Global Oral Transmucosal Drugs Market Attractiveness Analysis, by Route of Penetration, 2021–2031
Figure 11: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Sublingual Mucosa, 2017–2031
Figure 12: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Buccal Mucosa, 2017–2031
Figure 13: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Gingival Tissues, 2017–2031
Figure 14: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Palatal Tissues, 2017–2031
Figure 15: Global Oral Transmucosal Drugs Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 16: Global Oral Transmucosal Drugs Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 17: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Hospital Pharmacies, 2017?2031
Figure 18: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Retail Pharmacies, 2017?2031
Figure 19: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Online Pharmacies, 2017?2031
Figure 20: Global Oral Transmucosal Drugs Market Value Share Analysis, by Indication, 2020 and 2031
Figure 21: Global Oral Transmucosal Drugs Market Attractiveness Analysis, by Indication, 2021–2031
Figure 22: Global Oral Transmucosal Drugs Market Value (US$ Mn), Cardiovascular Disorders, 2017–2031
Figure 23: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Acute Pain Management, 2017–2031
Figure 24: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Sedation, 2017–2031
Figure 25: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Erectile Dysfunction, 2017–2031
Figure 26: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Diabetes, 2017–2031
Figure 27: Global Oral Transmucosal Drugs Market Value (US$ Mn), by Others, 2017–2031
Figure 28: Global Oral Transmucosal Drugs Market Value Share Analysis, by Region, 2020 and 2031
Figure 29: Global Oral Transmucosal Drugs Market Attractiveness Analysis, by Region, 2021–2031
Figure 30: North America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 31: North America Oral Transmucosal Drugs Market Value Share, by Country, 2020 and 2031
Figure 32: North America Oral Transmucosal Drugs Market Attractiveness Analysis, by Country, 2021–2031
Figure 33: North America Oral Transmucosal Drugs Market Value Share Analysis, by Type, 2020 and 2031
Figure 34: North America Oral Transmucosal Drugs Market Attractiveness Analysis, by Type, 2021–2031
Figure 35: North America Oral Transmucosal Drugs Market Value Share Analysis, by Route of Penetration, 2020 and 2031
Figure 36: North America Oral Transmucosal Drugs Market Attractiveness Analysis, by Route of Penetration, 2021–2031
Figure 37: North America Oral Transmucosal Drugs Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 38: North America Oral Transmucosal Drugs Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 39: North America Oral Transmucosal Drugs Market Value Share Analysis, by Indication, 2020 and 2031
Figure 40: North America Oral Transmucosal Drugs Market Attractiveness Analysis, by Indication, 2021–2031
Figure 41: Europe Oral Transmucosal Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 42: Europe Oral Transmucosal Drugs Market Value Share, by Country/Sub-region, 2020 and 2031
Figure 43: Europe Oral Transmucosal Drugs Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 44: Europe Oral Transmucosal Drugs Market Value Share Analysis, by Type, 2020 and 2031
Figure 45: Europe Oral Transmucosal Drugs Market Attractiveness Analysis, by Type, 2021–2031
Figure 46: Europe Oral Transmucosal Drugs Market Value Share Analysis, by Route of Penetration, 2020 and 2031
Figure 47: Europe Oral Transmucosal Drugs Market Attractiveness Analysis, by Route of Penetration, 2021–2031
Figure 48: Europe Oral Transmucosal Drugs Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 49: Europe Oral Transmucosal Drugs Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 50: Europe Oral Transmucosal Drugs Market Value Share Analysis, by Indication, 2020 and 2031
Figure 51: Europe Oral Transmucosal Drugs Market Attractiveness Analysis, by Indication, 2021–2031
Figure 52: Asia Pacific Oral Transmucosal Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 53: Asia Pacific Oral Transmucosal Drugs Market Value Share, by Country/Sub-region, 2020 and 2031
Figure 54: Asia Pacific Oral Transmucosal Drugs Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 55: Asia Pacific Oral Transmucosal Drugs Market Value Share Analysis, by Type, 2020 and 2031
Figure 56: Asia Pacific Oral Transmucosal Drugs Market Attractiveness Analysis, by Type, 2021–2031
Figure 57: Asia Pacific Oral Transmucosal Drugs Market Value Share Analysis, by Route of Penetration, 2020 and 2031
Figure 58: Asia Pacific Oral Transmucosal Drugs Market Attractiveness Analysis, by Route of Penetration, 2021–2031
Figure 59: Asia Pacific Oral Transmucosal Drugs Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 60: Asia Pacific Oral Transmucosal Drugs Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 61: Asia Pacific Oral Transmucosal Drugs Market Value Share Analysis, by Indication, 2020 and 2031
Figure 62: Asia Pacific Oral Transmucosal Drugs Market Attractiveness Analysis, by Indication, 2021–2031
Figure 63: Latin America Oral Transmucosal Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 64: Latin America Oral Transmucosal Drugs Market Value Share, by Country/Sub-region, 2020 and 2031
Figure 65: Latin America Oral Transmucosal Drugs Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 66: Latin America Oral Transmucosal Drugs Market Value Share Analysis, by Type, 2020 and 2031
Figure 67: Latin America Oral Transmucosal Drugs Market Attractiveness Analysis, by Type, 2021–2031
Figure 68: Latin America Oral Transmucosal Drugs Market Value Share Analysis, by Route of Penetration, 2020 and 2031
Figure 69: Latin America Oral Transmucosal Drugs Market Attractiveness Analysis, by Route of Penetration, 2021–2031
Figure 70: Latin America Oral Transmucosal Drugs Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 71: Latin America Oral Transmucosal Drugs Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 72: Latin America Oral Transmucosal Drugs Market Value Share Analysis, by Indication, 2020 and 2031
Figure 73: Latin America Oral Transmucosal Drugs Market Attractiveness Analysis, by Indication, 2021–2031
Figure 74: Middle East & Africa Oral Transmucosal Drugs Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 75: Middle East & Africa Oral Transmucosal Drugs Market Value Share, by Country/Sub-region, 2020 and 2031
Figure 76: Middle East & Africa Oral Transmucosal Drugs Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 77: Middle East & Africa Oral Transmucosal Drugs Market Value Share Analysis, by Type, 2020 and 2031
Figure 78: Middle East & Africa Oral Transmucosal Drugs Market Attractiveness Analysis, by Type, 2021–2031
Figure 79: Middle East & Africa Oral Transmucosal Drugs Market Value Share Analysis, by Route of Penetration, 2020 and 2031
Figure 80: Middle East & Africa Oral Transmucosal Drugs Market Attractiveness Analysis, by Route of Penetration, 2021–2031
Figure 81: Middle East & Africa Oral Transmucosal Drugs Market Value Share Analysis, by Distribution Channel, 2020 and 2031
Figure 82: Middle East & Africa Oral Transmucosal Drugs Market Attractiveness Analysis, by Distribution Channel, 2021–2031
Figure 83: Middle East & Africa Oral Transmucosal Drugs Market Value Share Analysis, by Indication, 2020 and 2031
Figure 84: Middle East & Africa Oral Transmucosal Drugs Market Attractiveness Analysis, by Indication, 2021–2031
Figure 85: Position Analysis, 2020, by Tier and Size of the Company
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Oral Transmucosal Drugs Market
